Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25325514 | 1.00 | GPR119 (0.39) | GPR119JAK2JAK1HTR7USP30 | |
| SCHEMBL30551491 | 1.00 | GPR119 (0.39) | GPR119JAK2JAK1HTR7USP30 | |
| SCHEMBL29477696 | 0.90 | HTR7 (0.39) | GPR119JAK2JAK1HTR7USP30 | |
| SCHEMBL24364263 | 0.90 | HTR7 (0.39) | GPR119JAK2JAK1HTR7USP30 | |
| SCHEMBL32689001 | 0.90 | HTR7 (0.39) | GPR119JAK2JAK1HTR7USP30 | |
| SCHEMBL24365984 | 0.88 | JAK2 (0.35) | JAK2JAK1HTR7USP30NR1H2 | |
| SCHEMBL32689250 | 0.88 | JAK2 (0.35) | JAK2JAK1HTR7USP30NR1H2 | |
| SCHEMBL29477731 | 0.88 | JAK2 (0.35) | JAK2JAK1HTR7USP30NR1H2 | |
| SCHEMBL25321644 | 0.87 | GPR119 (0.48) | GPR119JAK2JAK1USP30PARP1 | |
| SCHEMBL25321648 | 0.87 | GPR119 (0.48) | GPR119JAK2JAK1USP30PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | GPR119 1037/4885JAK2 531/4885JAK1 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.